CATALOGO DEI PRODOTTI DELLA RICERCA

ROSSOTTI, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 984
AS - Asia 285
EU - Europa 165
Continente sconosciuto - Info sul continente non disponibili 90
SA - Sud America 44
AF - Africa 11
OC - Oceania 1
Totale 1.580
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 941
IT - Italia 85
SG - Singapore 73
CN - Cina 69
HK - Hong Kong 50
BD - Bangladesh 28
CA - Canada 21
BR - Brasile 20
GB - Regno Unito 18
IQ - Iraq 14
IN - India 13
RU - Federazione Russa 13
DE - Germania 11
FR - Francia 11
AR - Argentina 8
NL - Olanda 7
VE - Venezuela 7
VN - Vietnam 7
CO - Colombia 6
PH - Filippine 6
IE - Irlanda 5
JM - Giamaica 5
MY - Malesia 4
SC - Seychelles 4
CR - Costa Rica 3
ES - Italia 3
LY - Libia 3
MX - Messico 3
SA - Arabia Saudita 3
TR - Turchia 3
BB - Barbados 2
BG - Bulgaria 2
EC - Ecuador 2
FI - Finlandia 2
ID - Indonesia 2
IL - Israele 2
KR - Corea 2
PK - Pakistan 2
SV - El Salvador 2
UA - Ucraina 2
AU - Australia 1
BE - Belgio 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BY - Bielorussia 1
CL - Cile 1
EE - Estonia 1
EG - Egitto 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
JP - Giappone 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
MM - Myanmar 1
MQ - Martinica 1
NP - Nepal 1
PR - Porto Rico 1
SE - Svezia 1
SZ - Regno dello Swaziland 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 1.491
Salva come PNG Salva come JPEG
Città #
San Jose 199
Council Bluffs 149
Ashburn 98
Singapore 49
Hong Kong 41
McKinney 25
Santa Clara 24
Milan 17
New York 17
Beijing 15
Rome 14
Los Angeles 13
Phoenix 13
Houston 11
Annandale 10
Cleveland 9
North Hollywood 9
Chicago 8
Dallas 8
Brooklyn 7
Erbil 7
London 7
New Delhi 6
San Francisco 6
Atlanta 5
Chandler 5
Jacksonville 5
Montreal 5
Moscow 5
North Bergen 5
Tampa 5
Ambérieu-en-Bugey 4
Caracas 4
Figino 4
Las Vegas 4
The Dalles 4
Bologna 3
Genoa 3
Hanoi 3
Naples 3
Palermo 3
Philadelphia 3
Toronto 3
Verona 3
Wilmington 3
Agrolândia 2
Baghdad 2
Belo Horizonte 2
Boston 2
Bridgetown 2
Buffalo 2
Denver 2
Dublin 2
Duhok 2
El Cajon 2
Helsinki 2
Ho Chi Minh City 2
Kajang 2
Kingston 2
Mexico City 2
Miami 2
Moreno Valley 2
Nampa 2
North Kansas City 2
Orem 2
Orlando 2
San José 2
San Juan 2
San Salvador 2
St Louis 2
Tel Aviv 2
Adamantina 1
Afragola 1
Ahoskie 1
Aiken 1
Alajuela 1
Allentown 1
Almaty 1
Amman 1
Angri 1
Apodaca 1
Athens 1
Athlone 1
Bari 1
Benghazi 1
Beverly 1
Billings 1
Birmingham 1
Bogor 1
Boise 1
Brampton 1
Brantford 1
Brockton 1
Buraidah 1
Bến Lức 1
Cairo 1
Calgary 1
Cambridge 1
Capaccio 1
Carmel 1
Totale 925
Salva come PNG Salva come JPEG
Nome #
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 103
A case of chronic bacterial prostatitis due toMycoplasma genitalium 90
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience 55
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 34
Implementation of HIV Pre-exposure Prophylaxis (PrEP) in Italy (2023-2024): Results from the PrIDE Cohort Survey 30
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 29
The burden of liver disease in human immunodeficiency virus-infected patients 28
A comparison of tenofovir predose concentrations in generic pre-exposure prophylaxis formulations: A short communication 26
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study 25
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 25
Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report 24
HIV infection among adolescents and young adults in Italy: epidemiology, viro-immunological and treatment outcomes 24
Is the rate of virological failure to cART continuing to decline in recent calendar years? 23
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 23
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 22
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 22
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 22
Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation 21
Medical and psychological needs for injectable long-acting cabotegravir as pre-exposure prophylaxis 21
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 21
Sexually Transmitted Hepatitis (cap. 13) 21
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500,000 copies/mL in 2018-2023 in Italy: data from the ICONA Foundation Cohort Study 20
Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1 20
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 20
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 20
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients 19
Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage 19
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients 19
Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP 19
The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period 18
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data 18
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 18
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 18
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 18
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy 17
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 17
Optimizing treatment in HIV/HCV coinfection 17
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 17
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 17
High prevalence of anal papillomavirus infection in men who have sex with men PrEP users 17
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 16
Correspondence: the recommended resistance-guided treatment of Mycoplasma genitalium infection in symptomatic individuals is not feasible in many Italian settings 16
A cluster of patients with recombinant B/F HIV-1 infection: Epidemiological, clinical, and virological aspects 15
Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report 15
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 15
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV 15
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection 15
Hepatitis A Virus in men who have sex with men: Need for awareness and vaccination 14
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy : Modeling from antiretroviral resistance cohort analysis (ARCA) national database 14
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 14
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 14
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 14
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 14
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 14
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis 14
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 13
Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs 13
Clinical management of ESBL-producing Enterobacteriaceae: The insidious role of fluoroquinolones 13
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 13
The use of intrahepatic portosystemic shunt in HIV positive patients : A retrospective multicentric study 13
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 13
Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject 12
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 12
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 12
Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics 12
HIV education and counselling using Facebook: A possible new approach 11
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results 11
Nevirapine-based regimens in routine clinical settings: Results from a large italian cohort of HIV-1 infected adults 11
Infezioni del fegato e delle vie biliari (cap.12) 11
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 11
A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays 11
Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy 11
Treatment of hepatitis C virus genotype 1-infected patients: Mission accomplished? 11
Enterococcus gallinarum endocarditis in a diabetic patient 10
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 10
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 10
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 10
Hepatocellular carcinoma in HIV hepatitis C virus 9
Human immunodeficiency virus and hepatitis c virus coinfection: The agenda is full while waiting for new drugs 9
Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy and autologous stem cell transplantation for T-cell lymphoma 8
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 8
Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy 8
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 6
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A casecontrol study 6
FDG-PET/CT imaging in the diagnosis of HIV-associated multicentric castleman disease: Something is still missing 6
Electrophysiological Adverse Effects of Direct-Acting Antivirals in Patients With Chronic Hepatitis C 5
Top topics in HCV research arena 5
Totale 1.580
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.152
article - articoli 15.790
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 362
Totale 32.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223 0 0 0 0 0 0 0 0 1 0 0 2
2022/202316 1 0 2 1 2 4 1 1 2 0 2 0
2023/20246 0 0 0 2 0 2 1 0 0 0 1 0
2024/202522 1 1 0 3 1 1 0 1 3 0 1 10
2025/2026623 5 2 2 7 13 3 3 1 53 441 32 61
2026/2027903 206 223 106 368 0 0 0 0 0 0 0 0
Totale 1.580